[PDF][PDF] Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy
O Fiala, M Pesek, J Finek, J Krejci, Z Bortlicek… - Neoplasma, 2013 - researchgate.net
Results of analysis show that even patients without EGFR mutation are able to benefit from
erlotinib treatment in the second line. The efficacy (DCR, PFS) of erlotinib in patients without …
erlotinib treatment in the second line. The efficacy (DCR, PFS) of erlotinib in patients without …
Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy
O Fiala, M Pesek, J Finek, J Krejci, Z Bortlicek… - …, 2013 - pubmed.ncbi.nlm.nih.gov
Molecular targeted therapy based on tyrosine kinase inhibitors, directed at the epidermal
growth factor receptor (EGFR) is one of novel options for management of NSCLC. Erlotinib is …
growth factor receptor (EGFR) is one of novel options for management of NSCLC. Erlotinib is …
Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.
O Fiala, M Pesek, J Finek, J Krejci, Z Bortlicek… - Neoplasma, 2013 - europepmc.org
Molecular targeted therapy based on tyrosine kinase inhibitors, directed at the epidermal
growth factor receptor (EGFR) is one of novel options for management of NSCLC. Erlotinib is …
growth factor receptor (EGFR) is one of novel options for management of NSCLC. Erlotinib is …